SCHEMBL8285684

SCHEMBL8285684

CCOC(=O)c1ccc2nc(N)n(Cc3ccc(F)cc3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
AGTR1 P30556 1/20 0.48
AGTR2 P50052 1/20 0.48
ALDH1A1 P00352 3/20 0.48
POLB P06746 1/20 0.48
HTT P42858 1/20 0.48
S1PR3 Q99500 1/20 0.48
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48
CDK2 P24941 1/20 0.48
KDM4E B2RXH2 2/20 0.47
PKM P14618 1/20 0.47
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
ALPL P05186 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
SOS1 Q07889 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8285685 0.91 ALDH1A1 (0.52) MAPTAGTR1AGTR2ALDH1A1POLB
SCHEMBL6171210 0.85 AGTR1 (0.62) MAPTAGTR1AGTR2ALDH1A1POLB
SCHEMBL6172093 0.82 LMNA (0.51) MAPTALDH1A1S1PR3KDM4EHPGD
SCHEMBL12226896 0.81 PDE2A (0.47) MAPTALDH1A1CDK1CDK4CDK2
SCHEMBL8284700 0.81 CA12 (0.45) MAPTALDH1A1CDK1CDK4CDK2
SCHEMBL6168901 0.80 MAPT (0.51) MAPTAGTR1AGTR2KDM4EPKM
SCHEMBL12226889 0.79 MEN1 (0.43) MAPTALDH1A1CDK1CDK4CDK2
SCHEMBL25297307 0.78 ALDH1A1 (0.50) MAPTALDH1A1POLBHTTKDM4E
SCHEMBL8284634 0.78 PDE2A (0.44) MAPTALDH1A1S1PR3CDK1CDK4
SCHEMBL30586473 0.78 ALDH1A1 (0.50) MAPTALDH1A1POLBHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 US disclosed
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 US disclosed
EP-1697343-B1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2009-07-01 EP disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 US disclosed
WO-2005058869-A1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 MAPT 4517/4885AGTR1 637/4885AGTR2 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.